PTP1B inhibition proved to be an effective strategy to improve the cellular signalling of both hormones and, therefore, the search for inhibitors of this enzyme could pave the way for the development of novel therapeutic agents for the management of T2DM and its associated pathologies, such as obesity and metabolic syndrome [17,18,19]. Here, PTPN1 is linked to type 2 diabetes mellitus.